Catalent, novo nordisk

Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the Federal Trade Commission decided not to challenge the deal. It’s expected to close in the coming days.
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.

Denmark, Novo Nordisk

BioPharma Dive37m
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...
BioSpace3h
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...
STAT2h
Viridian confirms benefit of drug for thyroid eye disease
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...
devdiscourse3h
Healthcare Innovations: Novo Nordisk's Strategic Moves and Emerging Drug Trends
Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...
Novo Holdings’ acquisition of Catalent gains EC approval
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...